Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7% ...

Grifols (GRFS) issued a statement to address certain information published in a media outlet on March 8, specifically a front-page article ...

Grifols revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Learn more on GRFS stock here.

Muddy Waters CEO Carson Block picked Grifols (GRFS) as a short for the Robin Hood Foundation’s stock picking contest. However, said in an ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other ...

Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous ...

Grifols has shared positive results from its clinical trial evaluating the efficacy and safety of intravenous immunoglobulin to treat patients with PPS.

Activist hedge fund Gotham lambasted healthcare firm Grifols last year. Some of its key criticisms were vindicated. And its ...

In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other pharma stocks. The Rising Demand for Weight-Loss Medications and GLP-1 Developments ...

More than two dozen people rallied on Monday against a new for-profit clinic in Whitby that pays people for plasma donations.

In response, Grifols, a global leader in plasma science and the production of plasma-derived medicines, has embarked on a groundbreaking program in partnership with The Michael J. Fox Foundation ...

In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other pharma stocks. Healthcare, which includes numerous businesses that offer patient care ...